IR Overview

Webcast ImageWebcast
Q3 2017 Adaptimmune Earnings Conference Call (Live)
11/02/17 at 8:00 a.m. ET
Q3 2017 Adaptimmune Earnings Conference Call
Thursday, November 2, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.

$7.04 Stock is Up 0.03 (0.43%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume137,565
Today's Open$7.02
Previous Close$7.01
Data as of 10/18/17 12:07 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
09/22/17James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
PHILADELPHIA and OXFORD, U.K., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink Partners Roundtable Series: Rare Disease and Immuno-oncology on Thursday, September 28, 2017 at 10:30 AM EDT (3:30 PM BST) in Holmes I/II at the Lotte New York Palace Hotel. The conference will be webcast live for investors thr... 
Printer Friendly Version
09/07/17GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled ... 
Printer Friendly Version
08/30/17Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210. The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy expert... 
Printer Friendly Version
08/03/17Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –        – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications – – On track for initial data from our wholly-owned assets in 2017 and 2018 –             – NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) c... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/02/17 8:00 a.m. ET
Q3 2017 Adaptimmune Earnings Conference Call
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.